Viva Biotech HoldingsFRA:VB0 +2.59%47 EBITDA Margin % is 29.92% as of Dec. 2025, which is 8% below its 10-year median of 32.64. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Viva Biotech Holdings ranks better than 89.7% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Viva Biotech Holdings EBITDA Margin % Related Terms
Viva Biotech Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a EBITDA Margin % of 29.92% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viva Biotech Holdings and its competitors. This is near median its historical median of 32.64. According to the industry distribution chart, Viva Biotech Holdings ranks #97 out of 942 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Viva Biotech Holdings' EBITDA Margin % too high?
Viva Biotech Holdings' current EBITDA Margin % of 29.92% is near median its 10-year median of 32.64. Based on the distribution chart, Viva Biotech Holdings ranks #97 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #97 out of 942 companies for EBITDA Margin %. This places Viva Biotech Holdings in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current EBITDA Margin % is 29.92%, which is near median its own 10-year median of 32.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current EBITDA Margin % is 29.92%, which is near median its 10-year median of 32.64. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current EBITDA Margin % is 29.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
EBITDA Margin %: 29.92% (near median its 10-year median of 32.64)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
